Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca
Status:
Recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess safety and feasibility of pre-operative
nivolumab in combination with either cabiralizumab, anti colony stimulating factor 1 receptor
(CSF1R) or BMS-986253 (anti-interleukin-8) in patients with squamous cell carcinoma of head
and neck (SCCHN) who will undergo surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins